ライフサイエンスコーパス: 111In

1 111In anti-myosin delineated reperfused infarcts within

2 111In introduced into triplex- and duplex-forming ODNs t

3 111In- and 177Lu-labeled J591 antibodies have similar pl

4 111In-DOTA-biotin was coinjected with 90Y-DOTA-biotin fo

5 111In-ibritumomab findings were positive in 19 patients

6 111In-Labeled antibodies and peptides have been routinel

7 111In-labeled oligonucleotides of high specific activity

8 111In-labeled platelets were infused after endarterectom

9 111In-leukocytes and 99mTc-N-IBoc-MLFK-HYNIC had compara

10 111In-platelet deposition on segments of homologous enda

11 od ecane-N,N',N",N"'-tetraacetic acid-Lym-1 (111In/90Y-2IT-BAD-Lym-1).

12 (NHL) received 111In- and 90Y-2IT-BAD-Lym-1; 111In was used as a surrogate tracer for 90Y, which emit

13 e time of adoptively transferred Indium 111 (111In)-labeled D4 cells in lungs of normal and HA-Tg mic

14 d the prognostic significance of indium-111 (111In)-capromab pendetide imaging for patients with pros

15 ty was observed, regardless of whether 125I, 111In, or 90Y was used.

16 Finally, the 125I/111In biodistribution data allowed for dose estimations,

17 w derivatives labeled with either with 68Ga, 111In, or 99mTc as thrombus imaging agents for PET and S

18 agent (sCA) at 48 or 72 h later, and (c) 90Y/111In-DOTA-biotin 24 h after the sCA administration.

19 iately and at 2-144 h after injection of 90Y/111In-DOTA-biotin.

20 atient-specific dosimetry of pretargeted 90Y/111In-DOTA-biotin after CC49 fusion protein in patients

21 The 90Y/111In-DOTA-biotin had a rapid plasma clearance, which wa

22 )4 and streptavidin, in conjunction with 90Y/111In-DOTA-biotin (DOTA = dodecanetetraacetic acid) prov

23 the disease stage) and consequently abnormal 111In-leukocyte uptake, should help avoid interpretation

24 the kinetic parameter estimates and absorbed 111In-MAb dose and projected 90Y-MAb doses for each pati

25 cyanate diethylenetriamine pentaacetic acid (111In-MX-DTPA) BrE-3 to specifically target breast cance

26 Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceti

27 Intravenously administered 111In-oxine-labeled naive DC actively migrated to and lo

28 localization of simultaneously administered 111In anti-myosin.

29 While not advocating 111In-WBC scintigraphy as part of the workup of epiglott

30 that diffuse peritonitis can mimic IBD on an 111In-leukocyte scan.

31 RP748, an 111In-labeled alphavbeta3 (active conformation)-targeted

32 easurements and gamma camera imaging with an 111In-labeled rat IgG2b monoclonal antibody directed aga

33 nonspecific imaging agents (p < 0.001), and 111In-immunoglobulin G had a higher T/B ratio than 111In

34 ions out to 1 h postinjection of 67/68Ga and 111In chelates of 4SS, 5SS, and 6SS were measured and co

35 The biodistributions of the 67/68Ga- and 111In-ligand complexes exhibited distinct trends.

36 ne, were prepared and labeled with 99mTc and 111In by a previously described method.

37 somes (liposomes labeled both with 99mTc and 111In) for the early detection of osteomyelitis in an ex

38 r after infection and dual photon (99mTc and 111In) gamma camera images were acquired at 2-3 and 16-1

39 The Abs were conjugated with biotin and 111In-benzyl diethylenetriamine pentaacetic acid, and, a

40 ected with 5-bromo-2-deoxyuridine (BrDU) and 111In-Z2D3 F(ab')2.

41 ompared with right tibia; with 111In Cl3 and 111In WBC the ratios are two times.

42 and compares the results with 111In Cl3 and 111In-WBC in an animal model.

43 ee-dimensional registration of pelvic CT and 111In-labeled monoclonal antibody capromab pendetide (11

44 68Ga-FBP14 and 111In-FBP15 have high fibrin affinity and thrombus speci

45 idneys, the highest uptake of 68Ga-FBP14 and 111In-FBP15 was in the thrombus (1.0+/-0.2 percentage in

46 experiments showed that both 68Ga-FBP14 and 111In-FBP15, but not the nonbinding derivative 64Cu-D-Cy

47 ted deposition of 125I-fibrin/fibrinogen and 111In-labeled platelets in the lung tissue of hypoxic co

48 Leukocytes labeled with 99mTc-HMPAO and 111In have been used extensively in imaging inflammatory

49 ere injected with 99mTc-N-For-MLFK-HYNIC and 111In-leukocytes with and without an excess of antagonis

50 re of 99mTc glucarate (15.7 +/- 1.6 mCi) and 111In anti-myosin (0.53 +/- 0.03 mCi) was administered i

51 rred on 67Ga citrate scans (18 patients) and 111In-tagged leukocyte scans (16 patients).

52 g the intravenous injection of 99mTc-PMN and 111In-anti-E-selectin MAb.

53 pretargeting approach using streptavidin and 111In-labeled biotin was used successfully to detect S.

54 nts were placed in the carotid arteries and [111In]-labeled platelets were circulated for 2 h.

55 ced or a-UPA-transduced ECs were measured as 111In-platelet deposition and 125I-fibrin accumulation o

56 The mean life span of autologous 111In-platelets was 87 +/- 39 hours (P = .0001 compared

57 creased TF RNA in hypoxic lungs, and because 111In-labeled murine MPs accumulated in hypoxic pulmonar

58 icant differences in biodistribution between 111In- and 90Y-labeled agents.

59 to 15% exist in the biodistribution between 111In- and 90Y-labeled antiTac.

60 d the differences in biodistribution between 111In- and 90Y-labeled murine antiTac MoAb directed agai

61 Sequential whole-body 111In images were acquired immediately and at 2-144 h af

62 etry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a

63 The presence of the bulky 111In-DTPA group did not impede duplex or triplex format

64 ty of the arterial specimens was assessed by 111In-labeled platelets.

65 oronary ligation, with trapping confirmed by 111In-labeled platelet autoradiographic imaging).

66 ne clearing agent, followed 4 hours later by 111In-DOTA-biotin.

67 area of known metastatic disease targeted by 111In-J591, with positive imaging seen in patients with

68 ition of small molecular weight catabolites, 111In and 90Y conjugates displayed superior retention of

69 he ionic repulsion of the negatively charged 111In-DTPA group from the DNA strands.

70 octreotide and a model nontargeted compound, 111In-DTPA-poly(D)lysine-biotin.

71 In contrast, 111In-DTPA-paclitaxel exhibited a pharmacological profil

72 spirin 10 mg.kg-1.d-1 alone did not decrease 111In-platelet and 125I-fibrin deposition on segments of

73 s of vascular graft but detectably decreased 111In-platelet and 125I-fibrin accumulation on stents (P

74 transit is currently performed by delivering 111In ion exchange resin pellets to the colon in a metha

75 y tested reference compound [Lys40-(AHX-DTPA-111In)NH2]exendin-4 and, thus, represent potential new t

76 4 was comparable to that of [Lys40-(AHX-DTPA-111In)NH2]exendin-4 at 1-48 h after injection.

77 -DFO-89Zr)NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 performed similarly well.

78 ments, clinically evaluated [Lys40-(AHX-DTPA-111In)NH2]exendin-4 was used as a reference compound.

79 As controls, each patients received either 111In-labeled biotin without the preadministration of st

80 similar when it was radiolabeled with either 111In or 90Y.

81 e-penta-a cetic acid and labeled with either 111In or 90Y.

82 were generated and radiolabeled with either 111In, 90Y, or 86Y.

83 ith 68Ga (FBP14, 68Ga-NODAGA), 111In (FBP15, 111In-DOTA-MA), or 99mTc (FBP16, 99mTc(CO)3-DETA-PA), re

84 , 21 and 68 for 99mTcP829, and 22 and 64 for 111In-[DTPA]octreotide.

85 at 90 min postinjection compared to 2.9% for 111In-[DTPA]octreotide).

86 We present radiation dose estimates for 111In-pentetreotide.

87 w showed a mean of 0.0029+/-0.0012 %ID/g for 111In, whereas the 90Y concentration was 0.0049+/-0.0021

88 58 percentage injected dose (%ID) x h/mL for 111In and 1.86%+/-0.64 %ID x h/mL for 90Y.

89 Thus, the pharmacokinetic data obtained for 111In-21T-BAD-Lym-1 in patients with NHL were used to ca

90 0.001), but did not affect the T/B ratio for 111In-leukocytes.

91 Biodistribution results were similar for 111In- and 90Y-labeled IgM.

92 enerated from the image data and scaled from 111In-CC49 to 90Y-CC49 for dosimetric purposes.

93 The average gamma ray count from [111In]-labeled platelets that attached to the coated ste

94 For-MLFK-HYNIC) plus 111In-immunoglobulin G, 111In-red blood cells or 111In-diethylene triamine penta

95 tes in the plasma of lymphoma patients given 111In- and 90Y-2-iminothiolane-2-[p-(bromoacetamido)benz

96 Compared with 111In-HIG, 111In-1.2B6 provided superior images in terms of sensiti

97 2B6 with that of nonspecific immunoglobulin, 111In-labeled polyclonal human immunoglobulin (HIG) was

98 ced cumulative (1) intermediate decreases in 111In-platelet and 125I-fibrin deposition for segments o

99 3H also outperformed all controls, including 111In-WBCs, 111In-DTPA, 131I-albumin, 99mTc-nanocolloid,

100 m (99mTc)-labeled PMN cells and (111)indium (111In)-labeled anti-E-selectin monoclonal antibody (MAb)

101 The TNFalpha-induced 111In-eosinophil accumulation was not affected after pre

102 ptor with metRANTES, significantly inhibited 111In-eosinophil recruitment in the allergic reaction.

103 -/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.

104 Irrelevant 111In-labeled human IgMlambda (CH-1B9) and 90Y-aggregate

105 the concept of a "matched pair" of isotopes, 111In is used as a surrogate markerfor90Y.

106 [(DOTA)Ser1,Leu8,D-Trp22,Tyr25]SS28} and its 111In radioligand.

107 These properties make 111In-cT84.66, or a lower molecular weight derivative, a

108 e obtained 24 hr after injection of 5.55 MBq 111In Cl3.

109 ities were acquired after injecting 5.55 MBq 111In-labeled WBC.

110 or a typical administered activity of 74 MBq 111In-antimyosin, the kidneys receive the highest dose (

111 ent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab

112 inistered a single intravenous dose of 5 mCi 111In-diethylenetriaminepentaacetic acid-cT84.66.

113 intravenous administration of 74 MBq (2 mCi) 111In-antimyosin, gamma camera scintigraphy was performe

114 ients received approximately 185 MBq (5 mCi) 111In-labeled antiTac for imaging and 185-555 MBq (5-15

115 -131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and Tc-99m-methylene diphosphonate

116 Furthermore, in non-tumor-bearing mice, 111In-DOTA hu4D5v8 minibody exhibited similar elevated u

117 In tumor-bearing mice, 111In-DTPA was characterized by rapid clearance from the

118 me imaging (2-4 mCi 99mTc and 75-125 microCi 111In), 99mTc-methylene diphosphonate (MDP) (3-5 mCi) an

119 In conclusion, the somatostatin mimic [111In-DOTA]LTT-SS28 specifically localizes in sst2-, sst

120 Significantly more 111In- than 125I-labeled antiTac(Fv)-PE38 accumulated in

121 In vivo, significantly more 111In- than 125I-labeled antiTac(Fv)-PE38 accumulated in

122 treatment was seen in patients with negative 111In-ibritumomab findings, whereas a higher rate of dis

123 by labeling with 68Ga (FBP14, 68Ga-NODAGA), 111In (FBP15, 111In-DOTA-MA), or 99mTc (FBP16, 99mTc(CO)

124 RP748, a novel 111In-labeled alpha(v)beta3-specific radiotracer, was ev

125 conjugate 111In-2IT-BAD-m170, 91% and 94% of 111In in the patients' plasma were in monomeric form, re

126 A previous study documented the ability of 111In-labeled 1,4-methyl-benzyl isothiocyanate diethylen

127 carcinoma demonstrated rapid accumulation of 111In-DTPA-octreotide in the pancreas and tumor.

128 y developing, dose-dependent accumulation of 111In-eosinophils in rat skin that was maximal at the do

129 The tumor accumulation of 111In-labeled antiTac(Fv)-PE38 at 96 h was 13-fold great

130 ted lysine reduced the renal accumulation of 111In-labeled antiTac(Fv)-PE38 by 62%.

131 increase in the ipsilateral accumulation of 111In-labeled platelets in mice subjected to stroke comp

132 counting, there was greater accumulation of 111In-labeled VEGF121 in ischemic than in control tissue

133 Dual isotope acquisition of 111In and 99mTc activities provides precise SPECT-SPECT

134 take, the effect of the specific activity of 111In-DOTA-biotin was evaluated.

135 Intravenous administration of 111In-labeled AC6C3-2B12 produced low tumor and high liv

136 weeks later by J591 with a reduced amount of 111In for additional PK measurements.

137 red as a diagnostic possibility for areas of 111In-leukocyte accumulation, particularly when expanded

138 ates for 90Y-J591 calculated on the basis of 111In or 177Lu data were mostly similar and showed that

139 to octreotide would downregulate binding of 111In-pentetreotide to sst and that this downregulation

140 the pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody.

141 onitor and quantify early biodistribution of 111In-oxine-labeled BM in a murine model of progenitor c

142 ibution, pharmacokinetics, and catabolism of 111In-labeled antiTac(Fv)-PE38 and found that it differe

143 N",N"'-tetraacetic acid for the chelation of 111In, 90Y, or 177Lu, or a technetium/rhenium chelate.

144 Metabolites and complexes of 111In-2IT-BAD-Lym-1 contributed a mean 10% of the total

145 cture of DNA damage produced by the decay of 111In incorporated into duplex and triplex DNA strands t

146 We have shown that decay of 111In produces highly localized DNA breaks.

147 odified Lym-1 followed by an imaging dose of 111In-21T-BAD-Lym-1.

148 A diagnostic dose of 111In-ibritumomab was administered on day 0, and imaging

149 e diagnostic dose or the therapeutic dose of 111In-pentetreotide.

150 r targeting with increasing protein doses of 111In-cT84.66 were not demonstrated, the results do sugg

151 4 h (P = 0.001), but later, the excretion of 111In was significantly greater (P = 0.001 to P = 0.04).

152 We evaluated the fate of 111In-DTPA-octreotide after it localizes in somatostatin

153 Images of 111In were of excellent quality; tumors and normal organ

154 used in this study, quantitative imaging of 111In-CC49 provided the data required for 90Y-CC49 dosim

155 tion, pharmacokinetics and immunogenicity of 111In-labeled cT84.66 as a function of administered anti

156 tion, pharmacokinetics and immunogenicity of 111In-labeled cT84.66.

157 The immunoreactivity of 111In-labeled antiTac was 90%+/-6%, whereas for 90Y-labe

158 Fifteen patients received an infusion of 111In-hMN-14 IgG.

159 at which time they received an injection of 111In Z2D3 F(ab')2 and underwent planar imaging.

160 We evaluated the internalization of 111In- and 125I-labeled antiTac(Fv)PE38 into ATAC4 cells

161 and significantly improved interpretation of 111In MoAb 7E11.C5 exams.

162 The distribution kinetics of 111In-containing CHEMS/DOPE/PEG-PE liposomes injected in

163 taacetic acid-cT84.66, labeled with 5 mCi of 111In.

164 ients, who received 111-185 MBq (3-5 mCi) of 111In-CC49, commenced in < 2 hr postinfusion and was con

165 ngly and in combination, for measurements of 111In-labeled platelets and 125I-labeled fibrin depositi

166 ndex was adversely affected by metabolism of 111In/90Y-2IT-BAD-Lym-1 to the extent that the tumor spe

167 Metabolites of 111In/90Y-2IT-BAD-Lym-1 accounted for 10% of blood AUC i

168 re intravenously administered 100 microCi of 111In-labeled recombinant human VEGF121, and biodistribu

169 At 3 d, the mean percentages of 111In in the patients' plasma in monomeric, metabolite,

170 nd in vitro data supported the processing of 111In/90Y-2IT-BAD-Lym-1 in the hepatocytes as the domina

171 ed at 24 and 72 hr to determine the range of 111In-CC49 activity concentrations in tumors and normal

172 ed for immunoreactive fraction, the ratio of 111In to 90Y in circulating cells was 1.11+/-0.17.

173 sies of tumor-involved skin showed ratios of 111In to 90Y of 0.7, 0.9 and 1.1.

174 at govern the target-to-background ratios of 111In-diethylenetriaminepentaacetic acid (DTPA) polypept

175 al controls), and immediate mean recovery of 111In-platelets injected into the systemic circulation w

176 We report on the results of 111In-labeled platelet scans in two such patients and re

177 The net retention of 111In activity by lung, liver, and spleen is slightly hi

178 In view of the established role of 111In-antimyosin in the detection of heart muscle pathol

179 Additionally, a spectrum of 111In-leukocyte and 99mTc-sulfur colloid uptake was note

180 f 90Y was significantly greater than that of 111In in the first 24 h (P = 0.001), but later, the excr

181 AC6C3-2B12 was two-fold greater than that of 111In-labeled CH-1B9.

182 ptake (14 +/- 1.8%) were lower than those of 111In-WBC.

183 Because of the long residence time of 111In-2IT-BAD-Lym-1 in tumors, high 90Y therapeutic rati

184 The uptake of 111In-21T-BAD-Lym-1 in tumors was greater than uptakes i

185 Uptake of 111In-alCAM-1 was greatest in the lung (approximately 10

186 ies, which failed to show abnormal uptake of 111In-antimyosin in localized sites of skeletal muscle i

187 cans were performed over 72 h, and uptake of 111In-antimyosin in organs was quantified using an atten

188 The tumor uptake of 111In-DOTA 10H8 minibody was 5.7 +/- 0.1% ID/g, similar

189 Furthermore, a significant uptake of 111In-DTPA-paclitaxel was observed in the tumor.

190 Tumor uptake of 111In-labeled AC6C3-2B12 was two-fold greater than that

191 Uptake of 111In-labeled antibody was 107.5+/-35.7, 135.9+/-70.8, a

192 this study was to investigate the uptake of 111In-labeled Z2D3 F(ab')2 in a swine model of coronary

193 11In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y.

194 ndings are supportive of our proposed use of 111In-ODNs for gene-specific radiotherapy.

195 bdominal site was facilitated by the use of [111In-DTPA-DPhe1]octreotide scanning for somatostatin re

196 r may be overestimated by about 25% based on 111In data.

197 and tumor 90Y doses were calculated based on 111In imaging data and the MIRD formalism using patient-

198 ylenetriamine pentaacetic acid (p < 0.01) or 111In-red blood cells (p = NS).

199 SS1scFvSA was labeled with 125I or 111In for evaluation of internalization in vitro and for

200 of radiolabeled (131I [n=2], 123I [n=1], or 111In [n=10]) antibody to MHC-II increased over baseline

201 X-A' ') for sequestering radiometals (86Y or 111In) and the near-infrared dye Cy5.5 for dual modality

202 commonly used radioisotopes (e.g., 99mTc or 111In) to activated charcoal in milieus that mimicked ga

203 adiolabeled with the SPECT isotopes 99mTc or 111In.

204 n-immunoglobulin G, 111In-red blood cells or 111In-diethylene triamine pentaacetic acid.

205 out the preadministration of streptavidin or 111In-labeled nonspecific IgG.

206 why such a large fraction of these and other 111In-DTPA-polypeptides accumulate in the liver and kidn

207 d the adoptive transfer of 111Indium-oxine- (111In-oxine) labeled P5-pulsed syngeneic dendritic cells

208 In two patients, 111In-pentetreotide scintigraphy detected liver lesions

209 eled monoclonal antibody capromab pendetide (111In MoAb 7E11.C5) images using 99mTc-labeled red blood

210 The lower yields of breaks per 111In decay compared with 125I may be not only the resul

211 e derived from serial whole-blood and plasma 111In concentrations.

212 ydrazinonicotinamide (N-For-MLFK-HYNIC) plus 111In-immunoglobulin G, 111In-red blood cells or 111In-d

213 therapy was noted in patients with positive 111In-ibritumomab findings.

214 rabbits were injected with freshly prepared, 111In(oxine)3 labeled single donor platelets through the

215 re acquired up to 7 d and used to quantitate 111In in organs and tumors.

216 tients who received the radioimmunoconjugate 111In-2IT-BAD-m170, 91% and 94% of 111In in the patients

217 ng agent, and (iii) 4 h later, radiolabeled (111In, 88Y/90Y, or 177Lu) 1,4,7,10-tetraazacyclododecane

218 Radioligand [111In-DOTA]LTT-SS28 showed good stability in the mouse b

219 d the diagnostic and therapeutic radiometals 111In and 88Y (and, by analogy, 90Y) with the required i

220 s with non-Hodgkin's lymphoma (NHL) received 111In- and 90Y-2IT-BAD-Lym-1; 111In was used as a surrog

221 Six patients received 111In/90Y-MX-DTPA BrE-3, three of them receiving 6.25 an

222 No patient that received 111In-2IT-BAD-Lym-1 developed antibodies to Lym-1 or DOT

223 in the plasma of every patient who received 111In-2IT-BAD-Lym-1.

224 gastrointestinal tract cancers who received 111In-CC49 IgG for imaging before therapy with 90Y-CC49

225 Recently [111In-DTPA-D-Phe1]-octreotide was approved for somatosta

226 y immunoblotting and immunostaining, reduced 111In-labeled platelet deposition (42% decrease, P < 0.0

227 TNFalpha therapy in RA significantly reduced 111In-labeled granulocyte migration into affected joints

228 For 67Ga-citrate, several 111In compounds, 131I-MIBG and 201Tl-thallous chloride,

229 Significant 111In-eosinophil recruitment was also observed in an act

230 , mMCP-5, or mMIP-1beta, induced significant 111In-eosinophil recruitment in mouse skin.

231 aacetic acid (DTPA) polypeptides, we studied 111In-DTPA-octreotide and a model nontargeted compound,

232 t not an antiMIP-1alpha antibody, suppressed 111In-eosinophil recruitment in this delayed-onset aller

233 as an imaging tool in tumors, we synthesized 111In-DEPA-paclitaxel and investigated its biodistributi

234 immunoglobulin G had a higher T/B ratio than 111In-diethylenetriamine pentaacetic acid (p < 0.01) or

235 Thus, it appears that 111In can be used as a surrogate marker for 90Y when lab

236 This density shift experiment indicated that 111In-DTPA-octreotide accumulated predominantly in hepat

237 We reported previously that 111In-labeled human monoclonal antibody, IgM 16.88 (In-I

238 These studies suggest that 111In-DTPA-paclitaxel may be clinically useful in studyi

239 These studies suggest that 111In-labeled antiTac(Fv)-PE38 can be used to trace the

240 The 111In-based biodistribution studies showed that all thre

241 The 111In-induced breaks were assayed in denaturing polyacry

242 The 111In-labeled H310A/H435Q protein exhibited the highest

243 olvement by prostate cancer suggested by the 111In MoAb examination could be interpreted with the bon

244 Corresponding estimates for the 111In-MAb were 3.18 (range, 2.09-4.43) and 0.55 (range,

245 f 1.86 +/- 0.19 was obtained at 48 hr in the 111In window.

246 ion protein (TNFR-IgG) totally inhibited the 111In-eosinophil accumulation induced by the cytokine.

247 MoAb, 5F10 (2 mg/kg), greatly inhibited the 111In-eosinophil accumulation induced by TNFalpha (the r

248 om clinical diagnostic studies involving the 111In-labeled monoclonal antibody (MAb) chimeric T84.66,

249 role for endogenous eotaxin in mediating the 111In-eosinophil recruitment in allergic inflammation, a

250 that registration in three dimensions of the 111In MoAb and CT images is achieved by applying the sam

251 cleotides from the site of attachment of the 111In-bearing linker.

252 The biodistribution of the 111In-DTPA cobalamin analogs was measured at 24 hr after

253 comes were compared with the findings of the 111In-ibritumomab scans.

254 Model-derived results based on the 111In-MAb blood, urine and digital imaging data were use

255 fractionation studies, demonstrated that the 111In-DTPA-poly(D)lysine-biotin compound accumulated in

256 ive tumor xenografted mice revealed that the 111In-labeled I253A fragment with the slowest clearance

257 This suggests that in each tissue, the 111In-DTPA-octreotide was rapidly shuttled from the cell

258 tumor, and when used in combination with the 111In-labeled peptide, radiation dose estimates for ther

259 The [111In]-labeled complexes can be prepared in good isolate

260 Therefore, 111In-based imaging studies can be used to predict the b

261 s and transplanted sarcomas when compared to 111In-DTPA.

262 normal human subjects is nearly identical to 111In-DTPA-IgG.

263 ords were reviewed for all men who underwent 111In-capromab pendetide imaging at a single institution

264 rnalization of antibodies, we decided to use 111In, which has greater intracellular retention than io

265 Using 111In pharmacokinetic data and 90Y physical constants, r

266 These results justify using 111In as a chemical and biologic surrogate for 90Y.

267 matostatin receptor scintigraphy done using [111In-DTPA-DPhe1]octreotide with single-photon emission

268 erformed all controls, including 111In-WBCs, 111In-DTPA, 131I-albumin, 99mTc-nanocolloid, 67Ga-citrat

269 onal methods, whereas small molecular weight 111In and 90Y catabolites remain trapped in lysosomes.

270 A low molecular weight 111In-DTPA-poly(D)lysine-biotin compound was synthesized

271 d with 125I (by the IodoGen method) and with 111In and 90Y using macrocyclic chelation technology.

272 of abnormal accumulation were apparent with 111In-IgG, but only in delayed images.

273 e groups of six rabbits were coinjected with 111In-leukocytes plus 99mTc-N-For-MLFK-HYNIC, 99mTc-N-Ac

274 Compared with 111In-HIG, 111In-1.2B6 provided superior images in terms

275 The three compounds labeled efficiently with 111In or (99m)Tc with high radiochemical purity and spec

276 e uptake in liver was about 20% greater with 111In than with 177Lu.

277 usly administered resin pellets labeled with 111In and activated charcoal mixed with 99mTc-diethylene

278 al administration of AC6C3-2B12 labeled with 111In or 90Y resulted in rapid, high tumor uptake (>45%

279 oclonal IgMlambda (AC6C3-2B12), labeled with 111In or 90Y.

280 M 16.88 and polyclonal IgG were labeled with 111In using a bifunctional chelating agent, LiLo.

281 DTPA-paclitaxel was labeled with 111In with a radiochemical yield of 84% and radiochemica

282 locytes, separated in vitro and labeled with 111In, was studied by analysis of gamma-camera images bo

283 ation of autologous lymphocytes labeled with 111In.

284 of a monoclonal antibody (Z2D3) labeled with 111In.

285 ected with streptavidin and, 2 h later, with 111In-labeled ethylene-diaminetetraacetic acid-biotin.

286 Carcinoid tumors can now be localized with 111In octreotide scintigraphy, which binds to the somato

287 e successfully labeled antiTac(Fv)-PE38 with 111In at up to 2.96 GBq/mg.

288 oxyribonucleotides (ODNs) were prepared with 111In attached by diethylenetriaminepentaacetic acid (DT

289 s indicate that radioimmunoscintigraphy with 111In-anti-CD4 is an excellent method for studying tissu

290 logically active human EGF radiolabeled with 111In and an anti-transferrin receptor monoclonal antibo

291 18F-FDG, the same peptide radiolabeled with 111In and pretargeted with the bs-mAb, and the radioiodi

292 sion protein with peptides radiolabeled with 111In, 90Y, 177Lu, and 99mTc.

293 Rosa 26 Lac Z+/+ mice was radiolabeled with 111In-oxine.

294 osteomyelitis, and compares the results with 111In Cl3 and 111In-WBC in an animal model.

295 Scintigraphy with 111In-labeled platelets has been used to identify increa

296 In animals studied with 111In-labeled antibody, uptake increased from 102.9+/-23

297 ad pharmacokinetics and imaging studies with 111In-J591 (185 MBq/20 mg) over a period of 1 wk and bef

298 use of monoclonal antibody Z2D3 tagged with 111In allows the detection of proliferating smooth muscl

299 99mTc-TPPS4 compared with right tibia; with 111In Cl3 and 111In WBC the ratios are two times.

300 ine and purine strands of DNA triplexes with 111In attached to the triplex-forming ODNs through the l